openPR Logo
Press release

Orphan Drugs Market Gaining a Strong Foothold 2026 Estimated By Key Players Acorda Therapeutics, Actelion Pharmaceuticals Ltd., Amgen, Alexion Pharmaceuticals, Baxter international, Bayer healthcare pharmaceuticals, Biomarin Pharmaceuticals

02-08-2019 07:42 AM CET | Health & Medicine

Press release from: Coherent Market Insights

Global Orphan Drugs Market

Global Orphan Drugs Market

Global Key Players:

Key players operating the orphan drugs market are Acorda Therapeutics, Actelion Pharmaceuticals Ltd., Amgen, Alexion Pharmaceuticals, Baxter international, Bayer healthcare pharmaceuticals, Biomarin Pharmaceuticals, Novartis, F.Hoffmann-La Roche AG, Johnson and Johnson and many others.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/500

The drugs which are developed for treatment of rare diseases and conditions are referred to as orphan drugs. The rare diseases such as Tourette syndrome, Huntington’s disease, muscular dystrophy, myoclonus, and ALS (Lou Gehrig’s disease) are some of those diseases for treatment of which adequate drugs have not been developed, and hence these diseases are treated by orphan drugs.

Orphan drugs are developed by the pharmaceutical companies for public health need, and the sales generated by this drugs are very minimal when compared to normal drugs. The orphan diseases manifest in patient populations representing 6-8% of the global population. Symptoms of some orphan diseases may appear at birth or in childhood including cystic fibrosis, infantile spinal muscular atrophy, familial adenomatous polyposis (FAP), and some others.

The Increasing Prevalence Of Rare Cancer In Patients Owing To Oncological Diseases Segment To Dominate In The Orphan Drugs Market:

The global orphan drugs market is segmented on the basis of disease, by product type and by region

On the basis of disease type:
Hematologic and Immunologic diseases
Infectious diseases, Metabolic diseases, Neurologic diseases, Oncologic diseases, Other orphan diseases

On the basis of product type:
Biological orphan drugs, Non-biological orphan drugs

Numerous Collaborative Research Programs Across North America And Europe Is Owing To Growth Of Orphan Drugs Market:

Regional segmentation of orphan drugs market by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America dominates the market globally due to factors such as established regulatory and reimbursement framework and incentives given by U.S. Food and Drug Administration (FDA) for research and development in orphan drugs sector.

The various collaborative research programs across United States and Europe provides research data on rare diseases to manufacturers, patients and health experts which gives timely medical care, thus boost the orphan drug market. Whereas the prevalence of genetic diseases and growth of population are some factors which might allow the orphan drugs manufacturers to invest in the Asia Pacific region.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/orphan-drugs-market-500

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Orphan Drugs Market Gaining a Strong Foothold 2026 Estimated By Key Players Acorda Therapeutics, Actelion Pharmaceuticals Ltd., Amgen, Alexion Pharmaceuticals, Baxter international, Bayer healthcare pharmaceuticals, Biomarin Pharmaceuticals here

News-ID: 1571321 • Views:

More Releases from Coherent Market Insights

U.S. Clinical Laboratory Services Market Exclusive Report with Detailed Study Analysis By 2025-2032 | Siemens Healthineers • Roche Diagnostics • Abbott Laboratories
U.S. Clinical Laboratory Services Market Exclusive Report with Detailed Study An …
Coherent Market Insights has released a report titled "U.S. Clinical Laboratory Services Market 2025-2032: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2032", which includes market percentage records and a thorough enterprise analysis. This report looks at the market's competition, geographic distribution, and growth potential. This comprehensive report encompasses industry performance, critical success factors, risk assessment, manufacturing prerequisites, project expenses, economic analysis, anticipated return on investment (ROI), and profit margins. ➤
Orthopedic Regenerative Medicine with Detailed Study Analysis 2025-2032 | Anika Therapeutics, Inc and Arthrex
Orthopedic Regenerative Medicine with Detailed Study Analysis 2025-2032 | Anika …
The Orthopedic Regenerative Medicine market is estimated to be valued at USD 11.68 Bn in 2025 and is expected to reach USD 23.79 Bn by 2032, growing at a compound annual growth rate CAGR of 10.7% from 2025 to 2032. ➤ The latest Qualitative Research Report on the Orthopedic Regenerative Medicine Market 2025, published by Coherent Market Insights, delivers in-depth insights into both global and regional markets, which are anticipated to
Asia Pacific Wound Care Biologics Market Growth in Future Scope 2025-2032 | Smith & Nephew Plc • Organogenesis Inc. • Integra LifeSciences Holdings Corporation
Asia Pacific Wound Care Biologics Market Growth in Future Scope 2025-2032 | Smit …
The Asia Pacific Wound Care Biologics market is estimated to be valued at USD 296.1 Mn in 2025 and is expected to reach USD 533.8 Mn by 2032, growing at a compound annual growth rate CAGR of 7.6% from 2025 to 2032. ➤ The qualitative latest Research report (2025-2032) on the Asia Pacific Wound Care Biologics Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges,
Future Scope of Premium Potting Soils Market Set for Significant Growth by 2025 - Comprehensive Competitive Landscape Through 2032
Future Scope of Premium Potting Soils Market Set for Significant Growth by 2025 …
The Premium Potting Soils market is estimated to be valued at USD 1,598.4 Mn in 2025 and is expected to reach USD 1,855.1 Mn by 2032, growing at a compound annual growth rate CAGR of 3.5% from 2025 to 2032. ➤ The Latest Report, titled Premium Potting Soils Market includes a detailed analysis of current market conditions, market players, regions, types, applications, Opportunity and Forecast 2025-2032. The report provides a detailed

All 5 Releases


More Releases for Orphan

Acquired Orphan Blood Disease Market
Acquired Orphan Blood Disease Market to reach over USD 18.93 billion by the year 2031 - Exclusive Report by InsightAce Analytic According to a new report by InsightAce Analytic, the "Acquired Orphan Blood Disease Market" in terms of revenue was estimated to be worth $8.65 billion in 2023 and is poised to reach $18.93 billion by 2031, growing at a CAGR of 10.47% from 2024 to 2031. Get Free Access to
Orphan Drugs Market Size to Hit $3199.3 Billion by 2028 | Orphan Drugs Industry …
Market Overview: According to our experience research team, Orphan Drugs Market was valued at USD 112.36 Billion in 2021, and the global Orphan Drugs industry is projected to reach a value of USD 3199.3 Billion by 2028, at a CAGR of 7.4% during the forecast period 2022-2028 Vantage Market Research is a collection of market research studies on several industries, such as Chemicals, semiconductors & Electronics, Food & Beverages Technology, Energy &
Orphan Drugs for Cancer Pipeline Analysis
A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developed
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the